Scholarlink

<p>Metastatic colorectal cancer is more than just one disease. With mandatory genetic analysis with respect to microsatellite instability high (MSIh) status, RAS and BRAFV600E mutations, first-line treatment options are determined by the molecular make-up of the tumors. In addition, patient derived factors, such as age, comorbidities and patient preferences influence the treatment intensity and treatment goals. Within these aims, special attention must be paid to oligometastatic disease as the window of opportunity of a&#xa0;potential secondary metastasectomy with curative intent should not be missed. In this article, the current developments of precision oncology and potential future advances are discussed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Das metastasierte Kolorektalkarzinom: eine komplexe Erkrankung mit zunehmend individualisierten Therapieansätzen

  • 期刊论文

  • 发表日期：

    2025年9月22日

查看全文
  • Sebastian Stintzing,
  • Dominik Modest

摘要

Metastatic colorectal cancer is more than just one disease. With mandatory genetic analysis with respect to microsatellite instability high (MSIh) status, RAS and BRAFV600E mutations, first-line treatment options are determined by the molecular make-up of the tumors. In addition, patient derived factors, such as age, comorbidities and patient preferences influence the treatment intensity and treatment goals. Within these aims, special attention must be paid to oligometastatic disease as the window of opportunity of a potential secondary metastasectomy with curative intent should not be missed. In this article, the current developments of precision oncology and potential future advances are discussed.